| scholarly article | Q13442814 |
| P50 | author | Peter Libby | Q22670611 |
| P2860 | cites work | Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis | Q46897070 |
| The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction | Q47288476 | ||
| Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice | Q47835280 | ||
| Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups "Atherosclerosis & Vascular Biology" and "Thrombosis". | Q50590519 | ||
| NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report. | Q50594261 | ||
| How Common Is Residual Inflammatory Risk? | Q51134355 | ||
| Requirement for CD154 in the progression of atherosclerosis. | Q52536870 | ||
| Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease | Q57243317 | ||
| Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability | Q58150063 | ||
| Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6 | Q58681737 | ||
| Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model | Q61960693 | ||
| Lack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice | Q62735862 | ||
| Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells | Q68827396 | ||
| Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1 | Q69743134 | ||
| Ligation of CD40 activates interleukin 1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta | Q73541937 | ||
| CD154 (CD40 ligand) | Q73902274 | ||
| Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice | Q74171931 | ||
| Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice | Q77231603 | ||
| Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist | Q81305498 | ||
| Deficiency of interleukin-1 receptor antagonist promotes spontaneous femoral artery aneurysm formation in mice | Q83242898 | ||
| Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) | Q85063666 | ||
| Informative Neutral Studies Matter-Why the Targeting Inflammation With Salsalate in Cardiovascular Disease (TINSAL-CVD) Trial Deserves Our Attention | Q87956210 | ||
| Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial | Q89400922 | ||
| Reduction of atherosclerosis in mice by inhibition of CD40 signalling | Q24316540 | ||
| Nucleotide sequence of human monocyte interleukin 1 precursor cDNA | Q24605740 | ||
| Interleukin-1 in the pathogenesis and treatment of inflammatory diseases | Q24606766 | ||
| Regulation of an inflammatory disease: Krüppel-like factors and atherosclerosis | Q26852339 | ||
| Targeting interleukin-1 in heart disease | Q27009347 | ||
| Gout-associated uric acid crystals activate the NALP3 inflammasome | Q28131797 | ||
| Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter | Q28771509 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Activation and regulation of the inflammasomes | Q29615664 | ||
| NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals | Q29615704 | ||
| Immunological and inflammatory functions of the interleukin-1 family | Q29619669 | ||
| Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice | Q30429015 | ||
| Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective | Q30884351 | ||
| Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries | Q31151434 | ||
| Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis | Q33404895 | ||
| Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation | Q33644572 | ||
| Inflammation in atherosclerosis: from pathophysiology to practice | Q33709505 | ||
| Why not treat human cancer with interleukin-1 blockade? | Q33833871 | ||
| MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. | Q33844451 | ||
| Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse | Q34091132 | ||
| Nomenclature of monocytes and dendritic cells in blood. | Q34125860 | ||
| Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. | Q34244878 | ||
| Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure | Q34322056 | ||
| Moderate hypoxia potentiates interleukin-1β production in activated human macrophages | Q34403101 | ||
| MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study | Q34415973 | ||
| Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes | Q34479098 | ||
| Inducible interleukin-1 gene expression in human vascular smooth muscle cells | Q34548807 | ||
| Use of canakinumab in the cryopyrin-associated periodic syndrome | Q34984749 | ||
| Inflammation and immunity in diseases of the arterial tree: players and layers | Q34988232 | ||
| Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1β-rich microparticles | Q35001472 | ||
| The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study | Q35059517 | ||
| Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype | Q35161070 | ||
| Discovery of small molecule CD40-TRAF6 inhibitors | Q35549406 | ||
| IL-1 and atherosclerosis: a murine twist to an evolving human story | Q35640654 | ||
| Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer | Q35786634 | ||
| Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? | Q35789870 | ||
| Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme | Q35796049 | ||
| Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids | Q35809793 | ||
| Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion | Q35835140 | ||
| Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies | Q35863952 | ||
| The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis | Q35864053 | ||
| Redundancy of IL-1 Isoform Signaling and Its Implications for Arterial Remodeling | Q35975645 | ||
| Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis | Q36028683 | ||
| Inflammation in atherosclerosis | Q36174933 | ||
| Targeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial Infarction | Q36296699 | ||
| Demonstration of a human pyrogen-inducing factor during mixed leukocyte reactions | Q36344789 | ||
| Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells | Q36352574 | ||
| Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene | Q36375747 | ||
| Adaptive immunity in atherogenesis: new insights and therapeutic approaches | Q36497196 | ||
| Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease: An Expanded "Cardiovascular Continuum". | Q36654171 | ||
| Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation | Q36691082 | ||
| Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases | Q36816872 | ||
| Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. | Q36816882 | ||
| NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis | Q36956703 | ||
| Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. | Q37233061 | ||
| Many cytokines are very useful therapeutic targets in disease | Q37316591 | ||
| Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling | Q37323724 | ||
| Inflammation and plaque vulnerability | Q37370224 | ||
| RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. | Q37445494 | ||
| Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis | Q37466366 | ||
| Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls | Q37810960 | ||
| Recent advances on the role of cytokines in atherosclerosis | Q37867358 | ||
| Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. | Q38008700 | ||
| Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response | Q38210436 | ||
| The inflammasome in myocardial injury and cardiac remodeling | Q38261433 | ||
| Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial | Q38394069 | ||
| Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial | Q38424365 | ||
| A Test in Context: High-Sensitivity C-Reactive Protein | Q38439507 | ||
| Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. | Q38475279 | ||
| Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial | Q38601785 | ||
| Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 | ||
| Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin | Q38747825 | ||
| Mechanisms of Myeloid Cell Modulation of Atherosclerosis | Q38812800 | ||
| Immune-mediated mechanisms of atherosclerosis and implications for the clinic | Q38851472 | ||
| Inflammasome Priming in Sterile Inflammatory Disease. | Q39097515 | ||
| Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions | Q39247885 | ||
| Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor | Q39760201 | ||
| CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation. | Q40256254 | ||
| Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Q40287836 | ||
| Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. | Q40600319 | ||
| Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. | Q40793696 | ||
| Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men. | Q40879721 | ||
| Activated platelets express IL-1 activity | Q41758080 | ||
| Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion | Q42494764 | ||
| Atheroprone flow activation of the sterol regulatory element binding protein 2 and nod-like receptor protein 3 inflammasome mediates focal atherosclerosis | Q42730137 | ||
| Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells | Q42752391 | ||
| Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis | Q42944624 | ||
| Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications | Q44278742 | ||
| Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution? | Q45002999 | ||
| Human vascular smooth muscle cells. Target for and source of tumor necrosis factor | Q45016501 | ||
| C-reactive protein levels and outcomes after statin therapy | Q45213511 | ||
| Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial | Q45369180 | ||
| Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. | Q45879983 | ||
| Low-dose colchicine for secondary prevention of cardiovascular disease | Q46245044 | ||
| Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice | Q46507912 | ||
| Murine "model" monotheism: an iconoclast at the altar of mouse | Q46643118 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 2278-2289 | |
| P577 | publication date | 2017-10-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond | |
| P478 | volume | 70 |
| Q90557447 | 3-Hydroxyanthralinic acid Metabolism Controls the Hepatic Srebp/Lipoprotein axis, Inhibits Inflammasome Activation in Macrophages, and Decreases Atherosclerosis in LDLR-/- Mice |
| Q101133026 | Age-related cerebral small vessel disease and inflammaging |
| Q92594570 | Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs |
| Q89664723 | An association between air pollution and daily most frequently visits of eighteen outpatient diseases in an industrial city |
| Q55331774 | Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond. |
| Q99552149 | Association between Neutrophil Percentage-to-Albumin Ratio and All-Cause Mortality in Critically Ill Patients with Coronary Artery Disease |
| Q89877488 | Associations of C-reactive protein and fibrinogen with mortality from all-causes, cardiovascular disease and cancer among U.S. adults |
| Q93212167 | Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multi-Ethnic Study of Atherosclerosis |
| Q93012793 | Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition |
| Q91868632 | Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages |
| Q57823938 | CHIP (Clonal Hematopoiesis of Indeterminate Potential) |
| Q52626862 | Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis and Atherogenesis. |
| Q90478690 | Cytokines at the Interplay Between Asthma and Atherosclerosis? |
| Q91644810 | Cytokines in Inflammatory Disease |
| Q104473891 | Distinct systemic cytokine networks in symptomatic and asymptomatic carotid stenosis |
| Q89964251 | Editorial: Targeting Monocytes/Macrophages to Treat Atherosclerotic Inflammation |
| Q61812564 | Effect of Interventional Therapy on IL-1β, IL-6, and Neutrophil-Lymphocyte Ratio (NLR) Levels and Outcomes in Patients with Ischemic Cerebrovascular Disease |
| Q90640923 | Ethyl acetate extract of sappanwood alleviates experimental atherosclerosis in rats through changes in FGF21 and SREBP-2 expression |
| Q92497929 | Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction |
| Q90181222 | From Focal Lipid Storage to Systemic Inflammation: JACC Review Topic of the Week |
| Q64093935 | Gene Ontology Analysis for Drug Targets of the Whole Genome Transcriptome of Human Vascular Endothelial Cells in Response to Proinflammatory IL-1 |
| Q89775507 | Genetics of age-related clonal hematopoiesis and atherosclerotic cardiovascular disease |
| Q90353963 | High-fat diet-induced kidney alterations in rats with metabolic syndrome: endothelial dysfunction and decreased antioxidant defense |
| Q92735271 | Immune cell phenotyping in low blood volumes for assessment of cardiovascular disease risk, development, and progression: a pilot study |
| Q98568327 | Impact of improving eating habits and rosmarinic acid supplementation on rat vascular and neuronal system in the metabolic syndrome model |
| Q89477733 | Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease |
| Q56337838 | Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty |
| Q57797462 | Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week |
| Q92103524 | Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology |
| Q56961974 | Innate and adaptive immunity in atherosclerosis |
| Q93158285 | Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity |
| Q57171783 | Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple |
| Q89576025 | Lipid and Non-lipid Factors Affecting Macrophage Dysfunction and Inflammation in Atherosclerosis |
| Q93052009 | Lysophosphatidylcholine Induces NLRP3 Inflammasome-Mediated Foam Cell Formation and Pyroptosis in Human Monocytes and Endothelial Cells |
| Q64071901 | Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer |
| Q93198168 | NLRP3 Inflammasome: A Potential Alternative Therapy Target for Atherosclerosis |
| Q92000753 | Novel Antiatherosclerotic Therapies |
| Q92652489 | Novel Insights Into the NLRP 3 Inflammasome in Atherosclerosis |
| Q60960345 | Nutrition and Cardiovascular Health |
| Q112720068 | Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate |
| Q90049837 | Parkinson's Disease: A Systemic Inflammatory Disease Accompanied by Bacterial Inflammagens |
| Q92126815 | Pro-inflammatory effects of crystalline- and nano-sized non-crystalline silica particles in a 3D alveolar model |
| Q88197027 | Recent major advances in cardiovascular pharmacotherapy |
| Q89668534 | Recombinant Lactococcus lactis Expressing Ling Zhi 8 Protein Ameliorates Nonalcoholic Fatty Liver and Early Atherogenesis in Cholesterol-Fed Rabbits |
| Q92239544 | Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases |
| Q92793755 | Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease |
| Q90638359 | Shenlian Extract Against Myocardial Injury Induced by Ischemia Through the Regulation of NF-κB/IκB Signaling Axis |
| Q99633698 | Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein |
| Q88646750 | Sodium Tanshinone II A Sulfonate for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials |
| Q91666473 | Sphingosine kinase-2 prevents macrophage cholesterol accumulation and atherosclerosis by stimulating autophagic lipid degradation |
| Q64059286 | Staphylococcal Superantigens: Pyrogenic Toxins Induce Toxic Shock |
| Q64087475 | Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease |
| Q49167115 | The Canakinumab Antiinflammatory Thrombosis Outcome Study trial-the starting gun has fired. |
| Q90084199 | The IL-1 family of cytokines and receptors in rheumatic diseases |
| Q64040507 | The angiotensin-(1-7)/Mas receptor axis protects from endothelial cell senescence via klotho and Nrf2 activation |
| Q51739082 | The antioxidant potential of the Mediterranean diet in patients at high cardiovascular risk: an in-depth review of the PREDIMED. |
| Q62711533 | The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis |
| Q47394893 | Treatment concentration of high-sensitivity C-reactive protein |
| Q92876664 | VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis |
| Q92287764 | [Immunity and inflammation in atherosclerosis] |
Search more.